ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 8 (4) 287-305    DOI: 10.1677/erc.0.0080287
Copyright © 2001 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (41)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arafah, B.
Right arrow Articles by Nasrallah, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arafah, B.
Right arrow Articles by Nasrallah, M.
Endocrine Related Cancer, Vol 8, Issue 4, 287-305
Copyright © 2001 by Society for Endocrinology

Articles

Pituitary tumors: pathophysiology, clinical manifestations and management

BM Arafah and MP Nasrallah


Pituitary tumors are frequently encountered intracranial neoplasms. They present with a variety of clinical manifestations that include symptoms and signs of excessive hormone secretion by the tumor, signs of hormone deficits by the normal pituitary gland and others related to expansion of the tumor mass and the resulting compression of surrounding structures such as the optic chiasm and cranial nerves. Advances in molecular biology, immunocytochemical staining and imaging, and the introduction of new treatment options have improved our understanding of the natural history of these adenomas and their management. Available treatments include surgical, medical and radiation therapy. Although the primary treatment for each tumor type may vary, it is important to consider all available options and select the most applicable for that patient. The interaction of all members of management team, including the primary care provider, the endocrinologist and the neurosurgeon in selecting the treatment course can only improve therapeutic outcome. Regardless of the initial choice of treatment,follow-up of all patients should be maintained indefinitely. The managing physician should be familiar with the natural history and long-term complications of pituitary adenomas, and with the side effects of treatments given over the years.


This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
R. N. Nawar, D. AbdelMannan, W. R. Selman, and B. M. Arafah
Analytic Review: Pituitary Tumor Apoplexy: A Review
J Intensive Care Med, March 1, 2008; 23(2): 75 - 90.
[Abstract] [PDF]

Home page
 Endocr Relat CancerHome page
A Raitila, M Georgitsi, A Karhu, K Tuppurainen, M J Makinen, K Birkenkamp-Demtroder, K Salmenkivi, T F Orntoft, J Arola, V Launonen, et al.
No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia
Endocr. Relat. Cancer, September 1, 2007; 14(3): 901 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Karhu and L. A. Aaltonen
Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update
Hum. Mol. Genet., April 15, 2007; 16(R1): R73 - R79.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. Ferone, R. Pivonello, E. Resmini, M. Boschetti, A. Rebora, M. Albertelli, V. Albanese, A. Colao, M. D Culler, and F. Minuto
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S37 - S43.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Georgitsi, A. Raitila, A. Karhu, K. Tuppurainen, M. J. Makinen, O. Vierimaa, R. Paschke, W. Saeger, R. B. van der Luijt, T. Sane, et al.
Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations
PNAS, March 6, 2007; 104(10): 4101 - 4105.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Gurlek, N. Karavitaki, O. Ansorge, and J. A H Wass
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics
Eur. J. Endocrinol., February 1, 2007; 156(2): 143 - 153.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M. A. Tichomirowa, and A. Beckers
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4769 - 4775.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. F. Daly, M.-L. Jaffrain-Rea, A. Ciccarelli, H. Valdes-Socin, V. Rohmer, G. Tamburrano, C. Borson-Chazot, B. Estour, E. Ciccarelli, T. Brue, et al.
Clinical Characterization of Familial Isolated Pituitary Adenomas
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3316 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Gutenberg, V. Hans, M. J A Puchner, J. Kreutzer, W. Bruck, P. Caturegli, and M. Buchfelder
Primary hypophysitis: clinical-pathological correlations.
Eur. J. Endocrinol., July 1, 2006; 155(1): 101 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Endocr. Rev., May 1, 2005; 26(3): 400 - 422.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J W Ironside
Best Practice No 172: Pituitary gland pathology
J. Clin. Pathol., August 1, 2003; 56(8): 561 - 568.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society for Endocrinology.